Skip to main content
. 2014 May 14;20(18):5483–5492. doi: 10.3748/wjg.v20.i18.5483

Table 3.

Treatment outcomes of acute superior mesenteric vein thrombosis patients n (%)

Outcome Overall (n = 25) Group 1 (n = 12) Group 2 (n = 13) P value
Morbidity
Bleeding 4 (16.0) 1 (8.3) 3 (23.1) 0.590
Wound infection 3 (12.0) 3 (25.0) 0 (0.0) 0.100
Acute kidney injury 4 (16.0) 2 (16.7) 2 (15.4) 1.000
Short bowel syndrome 5 (20.0) 5 (41.7) 0 (0.0) 0.020
Secondary portal hypertension 1 (4.0) 1 (8.3) 0 (0.0) 0.480
Cavernous transformation of the portal vein 2 (8.0) 2 (16.7) 0 (0.0) 0.220
Delayed or secondary operation 6 (24.0) 2 (16.7) 4 (30.8) 0.650
Bowel transmural necrosis 2 (8.0) 0 (0.0) 2 (15.4) 0.480
Bowel perforation 1 (4.0) 1 (8.3) 0 (0.0) 0.480
Bowel stricture 3 (12.0) 1 (8.3) 2 (15.4) 1.000
Laparoscopic surgery 4 (16.0) 0 (0.0) 4 (30.8) 0.100
Length of resection (cm)2 100 (range: 0, 155) 155 (105, 200) 0 (0, 65) < 0.001
Time from treatment to symptom elimination1 12.52 ± 7.85 18.25 ± 7.69 7.23 ± 2.42 < 0.001
Time from admission to enteral or oral nutrition (d)1 14.48 ± 6.98 20.50 ± 5.13 8.92 ± 1.89 < 0.001
Duration of hospitalization in (d)1 31.28 ± 15.51 43.00 ± 13.77 20.46 ± 6.59 < 0.001
Total cost in RNB1 133895.20 ± 90996.47 200020.40 ± 91505.62 72785.60 ± 21828.16 0.001
< 30-d mortality 24 (96.0) 11 (91.7) 0 (0.0) 0.480
1-yr survival 21 (84.0) 9 (75.0) 12 (92.3) 0.320
1

Analysis was performed by t test;

2

Mann-Whitney U test; or Fisher’s exact test.